|Bid||125.10 x 100|
|Ask||138.00 x 200|
|Day's Range||131.62 - 134.98|
|52 Week Range||123.73 - 192.15|
|PE Ratio (TTM)||9.50|
|Forward Dividend & Yield||1.05 (0.79%)|
|1y Target Est||N/A|
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
Shares of biopharmaceutical company Caladrius Biosciences Inc (NASDAQ:CLBS) are soaring nearly 25% to $6.35 in pre-market trading Tuesday. All of this appears to be a result of CLBS's announcement this morning that it has entered into a definitive agreement with Shire (NASDAQ:SHPG) to acquire a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. Valuation-wise, it's hard to say whether CMC is getting a good price on this asset. Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment of refractory angina. In exchange, Shire will receive undisclosed up-front consideration, milestones and a royalty on product sales.
Shire plc (LSE:SHP) delivered a less impressive 11.76% ROE over the past year, compared to the 16.09% return generated by its industry. An investor may attribute an inferior ROE toRead More...
The Soros Fund Management reportedly sold its entire holdings of Acadia Pharmaceuticals and Shire plc in the fourth quarter of 2017.
Shire plc’s (NASDAQ:SHPG) most recent return on equity was a substandard 4.97% relative to its industry performance of 16.36% over the past year. SHPG’s results could indicate a relatively inefficientRead More...
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.
Shire, which is splitting its rare disease and hyperactivity drugs into separate units, said 2018 sales would grow in mid-single figures and profits would rise at an even slower pace. The London-listed pharmaceuticals firm reported full-year revenue on Wednesday of $15.16 billion (10.94 billion pounds), up 33 percent, and non-GAAP diluted earnings per American Depositary Share of $15.15, up 16 percent and towards the top of its guidance. Chief Executive Flemming Ornskov said 2017 growth was boosted by a strong performance from its immunology medicines.
Shire, which is splitting its rare disease and hyperactivity drugs into separate units, said 2018 sales would grow in mid-single figures and profits would rise at an even slower pace. The London-listed pharmaceuticals firm reported full-year revenue on Wednesday of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per American Depositary Share of $15.15, up 16 percent and towards the top of its guidance. Chief Executive Flemming Ornskov said 2017 growth was boosted by a strong performance from its immunology medicines.
On a per-share basis, the Dublin-based company said it had profit of $10.22. Earnings, adjusted for one-time gains and costs, were $3.98 per share. The results surpassed Wall Street expectations. The average ...
Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after ...
Shire plc (LSE:SHP) is trading with a trailing P/E of 26.1x, which is lower than the industry average of 26.8x. While this makes SHP appear like a great stock toRead More...
Simon Property Group Inc (SPG), Ford Motor Co (F), Shire PLC (SHPG), and Public Storage (PSA) have declined to their respective three-year lows.
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".
Rare disease drugmaker Shire cut its 2020 revenue forecast on Monday, and announced that it plans to split its ADHD drugs into a separate division, with a possible spinout in the future. Shire (SHPG), the state’s second largest biopharma employer, said that it is now projecting its total revenue to reach $17 billion to $18 billion by 2020. Shares of Shire were down more than 4 percent as of 11 a.m., shaving nearly $2 billion off its market capitalization, which was around $45 billion before the selloff.